Immune Reconstitution and Long-Term Immunologic Changes Following Transitionfrom anti-CD20 Therapy
Study of Ocrelizumab vs. Diroximel for Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)
Sponsor: Biogen
Enrolling: Male and Female Patients
IRB Number: AAAU2756
Contact: Kaho Onomichi: 212-305-2434 / mscenter_neuro@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on ocrelizumab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after the last Ocrelizumab (OCR) dose, prior to beginning DRF. Baseline visits for individuals remaining on OCR will take place prior to OCR dose. Visits will occur every 6 months for 24 months (total of 5 study visits). Visits will include blood draw as well as clinical assessments.
Investigator
Rebecca Straus Farber, MD
Do You Qualify?
Are you between the ages of 18-60? Yes No
Have you been diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)? Yes No
Have you been on Ocrelizumab/Ocrevus for at least 2 years? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Kaho Onomichi
mscenter_neuro@cumc.columbia.edu
212-305-2434